Loss or attenuated expression of the tumor suppressor gene FHIT is associated paradoxically with poor progression of human tumors. Fhit promotes apoptosis and regulates reactive oxygen species, however, the mechanism by which Fhit inhibits tumor growth in animals remains unclear. In this study, we used a multi-discliplinary approach based on bioinformatics, small RNA library screening, human tissue analysis and a xenograft mouse model to identify a novel member of the miR-548 family in the fourth intron of the human FHIT gene. Characterization of this human-specific microRNA illustrates the importance of this class of microRNAs in tumor suppression and may influence interpretation of Fhit action in human cancer.
Introduction
The FHIT (fragile histidine triad) gene was identified in 1996 at FRA3B (1) that is wellknown as the most activated common fragile region. Common fragile sites in the chromosome regions are more susceptible to breakage, rearrangements and deletions than other sites in the genome. FHIT is frequently lost in different types of human tumors due to the alteration of FRA3B. Since FHIT was identified, several hundred scientific papers have been published to report FHIT deletion, low expression or promoter methylation in the majority of human cancers (2) (3) (4) (5) (6) (7) . It was also reported that Fhit deficient mice developed more tumors (8) . The association of Fhit to cancer was related to Fhit in promoting apoptosis and regulating the production of the reactive oxygen species (9) (10) (11) (12) . These discoveries demonstrate that FHIT is a tumor suppressor.
However, the results pertaining to the inhibitory effects of up-regulated Fhit on tumor growth are controversial (13) (14) (15) (16) , suggesting that additional mechanisms need to be elucidated. FHIT coding region distributing over 10 exons (~1,100 base pairs (bp)) encode a ~17 kD protein but the entire gene including non-coding portion with 9 introns is around 1.5 Mb. Since mis-regulated microRNAs (miRs) involved in cancer are frequently located at fragile sites (17) , we were interested in exploring whether the FHIT gene encoded any miR with an effect on inhibiting tumor growth. As a result, we identified a novel miR in FHIT intron 4, and found that this miR is a new member of the miR-548 family.
The miR-548 family is primate/human-specific (18) and derived from repetitive elements in the genome (19) . Until now, 68 members of the hsa-miR-548 family have been documented in the miRBase database of miR sequences (http://www.mirbase.org/) (not including the one described in this study) ( Table S1 ). The hsa-mir-548 is derived from Made1 transposable elements that are short miniature inverted-repeat transposable elements (MITEs) and consist of two 37 bp terminal inverted repeats that flank 6 bp of the internal sequence. Thus, Made1 elements are nearly perfect palindromes, and when expressed as RNA they form highly stable hairpin loops. Apparently, these Made1-related structures are recognized by the RNA interference enzymatic machinery and are processed to form ~22 bp mature miR sequences. The evolutionary lineage-specific nature of MITEs also provides for a generation of novel regulatory phenotypes related to species diversification. Similar to all other members of the family, the novel member expresses also relatively low when compared with most miRs in the human genome; however, the miR-548 family may contain >1000 members (as predicted and supported by this study). Our data showed that this new member in FHIT intron could have an accumulative function with multiple members of the miR-548 family towards inhibiting tumor cell growth. These results not only help us understand the function of the FHIT gene as a tumor suppressor but also reveal an important role of the unique miR-548 family in inhibiting human cancer development.
Materials and Methods

Prediction of the candidate miRs in the FHIT introns
The nine introns of the FHIT gene were extracted from the UCSC genome browser (20) . An ensemble classifier termed ABmiPred was constructed (21) using machine learning methods. 300 miR precursors (pre-miR) were randomly selected from miRBase for positive training samples.
44,500 pseudo pre-miRs were randomly selected from 57,994 pseudo pre-miRs derived from human 3'UTR sequences for negative training samples. The secondary structures of the FHIT introns were predicted using an RNAfold (22) in windows of 1,000 nucleotides with an overlap of 150 nucleotides. After removing the hairpins with MFE greater than -15kcal/mol, 3,440 hairpins were obtained. Among them, 190 hairpins were predicted as pre-miR candidates at a threshold of 0.5 with known miRs (miRBase release 13) (23), fRNAdb3 (24) and NONCODE2 (25) , which homologous sequences were compared using BLAST. Finally, four predicted premiR candidates that were homologous to bona fide miRs and conserved non-coding regions were taken as our miR candidates.
Plasmids construction and packaging
To construct a plasmid expressing the new member of the miR-548 family and other miRs, we amplified the precursor miR (pre-miR) with 100 bp context flanked sequence on each side using the human genomic DNA (Promega) with the different primers (Table S4 ) according to the procedure described previously (26) . The amplified fragment was first cloned into a PCR cloning vector and subsequently into pIRES2-EGFP (Clontech) at BamH I and Sal I sites and the lentiviral vector pCDH-CMV-MCS-EF1-copGFP (System Biosciences, Mountain View, CA, USA) at the EcoR I and BamH I sites. The plasmid packaging was as described previously (26) .
The luciferase-UTR reporter plasmid that contains the 3'UTR of CCND1, ERBB2, DNMT3A or DNMT3B that carry a putative new miR binding site or a deleted mutant without the new miR binding site was constructed with the complementary oligonucleotides (Table S4 ) and inserted into a modified pGL3-control plasmid firefly luciferase vector (Promega).
Northern blot
The total RNA was extracted from 293FT or HeLa cells. Twenty microgram of total RNA was separated in 1% of agarose gel (containing 50 μg ethidium bromide in 100 ml gel). The RNA marker was purchased from Sigma-Aldrich Inc. After transferring to a nylon membrane (GE Healthcare), the membrane was hybridized with a special probe, 5'-GTTGCCATTA CTTTCAAGGGCAAAAACCATAGTTACTTTTGTACCAATCTGATATTTTTCTTCCAA-3'-Dig (for detecting the pri-miR at chromosome 1), or 5'-TTAGCTTGGTGCAAAAGTAAC TATGGTTTTTGGGCAAAAACCATAGTTACTTTTGCACCAATCTAA-3'-Dig (for detecting the pri-miR at chromosome 3). The membrane was soaked in a solution containing the DIG antibody and followed a procedure according to the manufacturer's instructions (DIG Wash and Block Buffer Set, Roche). The signals were obtained by exposing the membrane to X-ray films at room temperature. Salisbury, UK) 6 years ago. L02 (liver cells), was as described previously (27) . 3KT (hTERT immortalized cells) were obtained from Dr. Jerry Shay's lab (28) . M059J and M059K (brain tumor cells) were obtained from Dr. Allalunis-Turner's lab (29) . The lung cancer cell lines, 95C and 95D, were obtained from Dr. Yinglin Lu's laboratory as described previously (26) . The other human lung cancer cell lines (H460, H358, H157, H1792, Calu1, H266B and SK-MES-1) were obtained from Dr. Shi-Yong Sun's laboratory (30) . All the human cells lines were tested within 6 months before starting this project by subcutaneously injecting individual one into nude mice (three injections for one cell line) to confirm whether they were tumorigenesis at 30 days after injection. Human lung tissues were obtained from the pathology facility at Emory, (30 pairs) and from the Department of Pathology, at the PLA General Hospital, Beijing, China (15 pairs).
Xenograft mouse model
The animal protocol was approved by the Emory University Institutional Animal Care and Use Committee (IACUC). The experiment was carefully performed following Emory University IACUC guidelines for animal care. Similar to our previous report (26) , both hind legs of each nu/nu mouse (male, 2 month-old, bodyweight ~22 g, purchased from the Jackson Laboratory, Bar Harbor, Maine, USA) were subcutaneously injected with 3x10 
Statistical analysis
Statistical analysis of data between two groups was done using the Student's t test or the Mann-Whiney U test when a normal distribution could not be assumed. One-way ANOVA was used for multiple group comparisons. The correlation coefficients were analyzed by Spearman's rho. Statistical calculations were performed using SPSS 13.0. Differences with P values less than 0.05 were considered statistically significant.
Results
Identification of a novel human miR in the FHIT intron
To examine whether FHIT encoded any miRs, we searched the 9 introns of FHIT in the human genome. As a result, we found 4 predicted pre-miRs that were highly similar with bona fide miRs and conserved non-coding regions ( as a real miR, we sub-cloned the PCR product of C2-miR into pMD18-T, sequenced and analyzed it. These results verified that C2-miR (with 22 nucleotides (nt)) is a novel miR and belongs to the miR-548 family since it is similar to 2 members of the miR-548 family, miR548d-5p and miR-548d-3p ( Fig. 1D and Table S1 ).
When performing a complete human genomic sequence search, we found that there was another identical 22nt sequence (C2-miR*) on chromosome 1 (Chr1) in addition to chromosome 3 (Chr3) (FHIT gene located) (Fig. S1D) . Although the extended sequence on chromosome 1 could not form a pre-miRNA (stem loop) structure, to exclude any possibilities that make the sequence expression, we compared the stably expressing levels of the two constructs (containing the 22nt on Chr1 or Chr3 with ~100 bp context flanked sequence on each side) in 293FT, A549, H1299 and HeLa cells (Fig. S1D, E) . The results showed that the Chr3 construct highly expressed but the Chr1 construct did not express in these cell lines (Fig. 1E) ; supporting that chromosome 3 (the FHIT intron) is the function location of the new miR. The Northern blot data provide additional evidence to support the conclusion (Fig. 1F) . Also, both strands of C2-miR expressed similarly ( To verify that C2-miR and the FHIT mRNA were controlled by the same promoter, we examined the effects of some promoter modifications on the expression of C2-miR and the FHIT mRNA. First, we used 5-Azacytidine (5-AZA), a DNA methylation inhibitor (33) , to treat the lung cancer cell line, H1299, and then measured the levels of the FHIT mRNA and C2-miR using qRT-PCR since it was reported that the Fhit expression increased in the cell line after 5-AZA treatment (34) . The results showed that after the cells were treated with 5-AZA, both the levels of the FHIT mRNA and C2-miR increased with a similar ratio (Fig. 2D) . We then upregulated TNFα, one of FHIT transcription factors, to stimulate FHIT expression in 293FT cells and measured the levels of the FHIT mRNA and C2-miR. SOD2, a known transcriptional target of TNFα, was used as a positive control. The results showed that TNFα stimulated the levels of the FHIT mRNA and C2-miR with a similar ratio (Fig. 2E) . These results strongly support that C2-miR and FHIT are under the same transcriptional control. However, we did find that the levels of mature C2-miR were much lower than the levels of the FHIT mRNA in the same samples.
To study whether any mutation resulted in the low expression level of C2-miR, we performed a detailed search in FHIT including intron 4 (C2-miR location) using the UCSC Genome Browser (hg19) with the COSMIC database from Sanger-Catalouge of Somatic Mutations in TCGA (The Cancer Genome Atlas) from NCI (35) . The results showed that FHIT contains 25 somatic substitutions and 9 break points, and intron 4 contains 1 somatic substitution and 3 break points (Fig. S2A, B ). There is a common marked single-nucleotide polymorphism (SNP): "A" or "C" in pre-C2-miR but no mutation is found around the C2-miR region (Fig. S2C) .
After sequencing the pre-C2-miR region in four cell lines (293FT, HT-144, DU145 and H157), we found two of them (293FT and H157) with "A" and two of them (DU145 and HT-144) with "C" (Fig. S2D) , confirming that this SNP is common. We also showed that neither the "A" SNP nor the "C" SNP affects the mature C2-miR expression (Fig. S2E) . These results exclude the possibility that any mutation in pre-C2-miR results in the low expression of C2-miR.
The miR-548 family including C2-miR showed an inefficient maturation process
Considering the low expression is a common characteristic among all the members of the miR-548 family, we hypothesized that the actually low expression of the miR-548 family including C2-miR is due to an inefficient maturation process. To test this hypothesis, we first made several standard curves of FHIT cDNA, pri-C2-miR, mature C2-miR, pri-miR-21 and mature miR-21 using different amounts of mimics, plasmid encoding FHIT cDNA (31) or primiRs by qRT-PCR (Fig. S3A) . Based on the standard curves, we compared the endogenous expression levels of C2-miR and FHIT in 293FT cells and A549 cells. The results showed that the expression percentage of C2-miR to FHIT cDNA in 293FT cells is 1.6% (Fig. 3A and Table   S2 ), confirming that the endogenous mature C2-miR level was much lower than Fhit in human cells, and suggesting that the low C2-miR level might be due to an inefficient maturation process 
since we already showed the same transcription regulation of the FHIT mRNA and C2-miR (Fig.   2D, E) .
We then compared the exogenous C2-miR and miR-21 in 293FT cells after the cells were transfected with the same molecular amount of the plasmid encoding an extended pre-miR with 100 bp context flanked sequence on each side (Fig. 3B ) by using the standard curves (Fig. S3A) .
The results showed that although the exogenous pri-C2-miR levels were higher (~6 fold) than the exogenous pri-miR-21 levels (Table S3) , the exogenous mature C2-miR levels were much lower than the exogenous mature miR-21 (roughly a ~83 fold difference) in 293FT cells (Fig. 3C and Table S3 ). Similar results (highly pri-miR levels but lowly miR levels) were observed in other 2 members of the miR-548 family: miR-548d and miR-548e (data not shown). These results indicate that the low expression of C2-miR is not due to an inefficient transcription but is related to an inefficient mature process for generating mature C2-miR, suggesting that the low expression of miR-548 family is through a same mechanism.
We next examined the effects of over-expressing FHIT cDNA or C2-miR on the levels of C2-miR or Fhit/FHIT. The results showed that over-expressing the coding region of FHIT did not affect the C2-miR level (Fig. 3B) , however, up-regulating C2-miR clearly increased the Fhit expression level (Fig. 3D) . After the cells were treated with 5-AZA, the C2-miR stimulated-FHIT/Fhit expression disappeared (Fig. 3E) , which indicates that the effects of C2-miR on promoting the Fhit expression are involved in demethylation of the FHIT promoter, suggesting that C2-miR targets some methylation enzymes. 
To examine whether C2-miR has any function to affect tumor growth, we used three human tumor cell lines: HeLa (without Fhit expression), A549 (with normal Fhit expression) and H1299 (with low Fhit expression) that were overexpressed with pri-C2-miR or the control vector (Fig.   1E ). The cell transfection efficiency was observed with the GFP signals (Fig. S4A) , and the C2-miR expression levels were as described by qRT-PCR (Fig. 1E, C2-miR-Ch3) . We then examined the tumor cell growth. At the same time, we also included the HeLa cells overexpressed with Fhit (31) since it was previously reported that up-regulating Fhit expression in HeLa cells did not inhibit HeLa cell growth in vitro (tissue culture) and in vivo (xenograft mouse model) (15) . The results showed that after C2-miR was up-regulated in these human tumor cell lines (Fig. 1E and Fig. S4A ), the tumor cell growth was much slower than their vector alone or FHIT cDNA transfected counterparts (Fig. 4A-C) . Notably, the effects of C2-miR on cell growth inhibition were abolished when the cells were treated with the C2-miR inhibitor (22 nt antisense of C2-miR) but not affected with a control RNA (22 nt) (Fig. 4A-C) , supporting the specific inhibition effects of C2-miR on tumor cell growth. On the other hand, the apoptosis ratio had no significant difference among these cell lines without any stress stimulation (Fig. 4D) , excluding the possibility that C2-miR inhibiting tumor cell growth is through promoting apoptosis. The FHIT cDNA overexpression in HeLa cells did not dramatically affect the xenograft size and weight (Fig. 4E) , which was similar to that previously reported (15), however, C2-miR overexpression significantly suppressed HeLa cell growth in vitro and in vivo (Fig. 4C,   E ). The immunohistochemistry data showed that the Ki67 signal (a marker for cell proliferation) but not the Caspase3 signal (a marker for cell apoptosis) was greatly decreased in the xenograft tumor derived from HeLa cells overexpressed with C2-miR but not with Fhit (Fig. S4B) . These results support that C2-miR but not Fhit could inhibit tumor cell growth. 
C2-miR inhibited human tumor growth through targeting CCND1, ERBB2, DNMT3A and
DNMT3B
To look for the C2-miR targets related to the stimulated tumor growth, we focused on Cyclin D1 (encoded by the CCND1 gene), ErbB2 (encoded by the ERBB2 gene) and DNMT3A and DNMT3B. The reasons for picking up these genes are as follows: 1) We previously found that the expression of Fhit and Cyclin D1 (encoded by the CCND1 gene) was significantly opposite in human cholangiacarcinoma (36); 2) It was reported that the 3'UTR of ERBB2 had a binding site for miR-548d-3p (one member of the miR-548 family) (37); 3) C2-miR promoted Fhit expression through demethylating the FHIT promoter (Fig. 3D, E (Fig. S5A) . The luciferase assay verified that these potential sites at 3'UTR of these genes were the real ones for C2-miR/C2-miR* binding (Fig. 5A ) and the Western blot data further confirmed that CCND1, ERBB2 DNMT3A and DNMT3B are C2-miR targets (Fig. 5B, lane 1 and   lane 2) . Also, the relatively high level of Cyclin D1 or ErbB2 in the human lung tumor samples with a low expression of C2-miR (Fig. S5B) ; and the effects of the C2-miR inhibitor on the expression levels of these targeted genes provide additional evidence for C2-miR targeting these genes. (Fig. 5B, lane 3 and lane 4) . transfecting CCND1, ERBB2, DNMT3A or DNMT3B without 3'UTR into the tumor cells that already over-expressed with C2-miR could successfully up-regulate the levels of Cyclin D1, ErbB2, DNMT3A or DNMT3B (Fig. 5B , lane 5, lane 6 and Fig. S5C ) and partially reversed the inhibitory effects of C2-miR on the tumor cell growth in vitro (Fig. S5D) and in vivo (Fig. 5C ).
These results strongly support that the role of C2-miR in inhibiting tumor cell growth is associated with targeting CCND1, ERBB2 or DNMT3A/DNMT3B.
The accumulative effects of the miR-548 family including C2-miR on targeting oncogenes and inhibiting tumor development
The endogenous level of C2-miR, similar to the other members of the miR-548 family, is relatively low in human cells; however, the members of the family share very conservative sequence at the targeting gene region (19) and it is known that multiple miR could target one mRNA in clusters or different locations (42), we were interested in study whether the members of the miR-548 family could cooperate together to inhibit human tumor growth. To test the hypothesis, we first requested NanoString Inc with the available color probes to measure the levels of 19 members of the miR-548 family that covered 29 mature members in the family (Table S5 ) and miR-21 (as a control) in 30 pairs of human lung tissues and 24 human cell lines using their sensitive technology (Fig. S6A) (43) . Since each individual member of the miR-548 family expressed relative low, we accumulated the total expression levels from all the miR-548 family members as one count from each sample and compared the ratio of the miR-548 family levels in tumor tissue/cells and in their non-tumor counterparts. The results showed that the relative levels of the miR-548 family were lower in most tumor tissue or tumor cells than in their non-tumor counterparts (Fig. 6A, B) , which is similar to that of C2-miR in these samples ( 2), suggesting that the members of the miR-548 family including C2-miR may work together to play an accumulative role in inhibiting human tumor development. Our qRT-PCR data verified the accuracy of NanoString's measurement (Fig. 6C and Fig. S6B ). These results confirm the expression levels of the miR-548 family that we measured in human tumor tissue and cells.
To explore the importance of the miR-548 family, we predicted the total numbers of the miR-548 family in the human genome. Considering both sequence and structural requirements for miR, 1182 putative sequences were found with > 50% sequence identity over the full-length of the canonical hsa-mir-548 sequence (Supplementary Methods and Fig. S6C ). These results strongly support that although the expression levels of the miR-548 family members are much lower than the regular miRs in human cells, this miR family with its >1000 members could have an important biological effect on suppressing tumors through an accumulation of their members.
To find out whether other members of the miR-548 family could be similar to C2-miR to target the same oncogenes, we examined the effects of 36 commercially (GeneCopoeia) available plasmids encoding GFP and 36 individual members of the miR-548 family on the ErbB2 levels in 293FT cells after the cells were transfected with the plasmid. The results showed that among the 36 member (of the miR-548 family) up-regulated cells, 19 of them showed lower ErbB2 expression than GFP vector alone-transfected cells (Fig. S6D) , supporting the conservative target of the miR-548 family. Based on these results, we further examined the effects of the 19 members of the miR-548 family on the levels of Cyclin D1, ErbB2 and DNMT3B after transfecting them into A549 cells. The results showed that the lower expressions of ErbB2, Cylcin D1 and DNMT3B were observed in most samples after the cells were transfected with the miR-548 members (Fig. S6E ). These results demonstrate that different CAN-13-3279 members of the miR-548 family could target the same oncogenes, suggesting an accumulative effect of the miR-548 family on inhibiting human tumor development.
To verify the hypothesis, we compared the growth change in A549 or H1299 human tumor cell lines that were solely-transfected with C2-miR alone or co-transfected with the 10 miRs (the C2-miR amount in the co-transfection mixture was 1/10 of the amount in the sole-transfection).
The results showed that although the C2-miR level in the cells co-transfected with the 10 miR mixture was only 1/10 of that in the cells solely-transfected with C2-miR (Fig. 6D) , the inhibitory effects of C2-miR on tumor cell growth were comparable between the cells solelytransfected with C2-miR or co-transfected with the 10 miR mixture (Fig. 6E) . These results strongly support that C2-miR could play an accumulative role with other members of the miR-548 family in inhibiting tumor cell growth, suggesting the importance of the miR-548 family in suppressing tumor development.
Discussion
FHIT is located at FRA3B (1) member of the miR-548 family in the FHIT intron, as described in this study, adds importance to FHIT as an important tumor suppressor at the fragile site.
Our results suggest that the relatively low levels of mature miR-548 members are not due to the transcription regulation but are related to the inefficient RNase processes. The inefficient RNase process might be related to the 3' or 5' repeated "A" or "U" in the sequence of the miR-548 family members. However, the mechanism involved in whether the process from pri-miR to pre-miR or the process from pre-miR to mature miR, needs the future experiments to elucidate.
Hsa-mir-548 is a multi-copy family of human miR genes. The expression levels of the mature miR-548 members are relatively low when compared with most other miRs in the human genome, for example, the CT value for miR-21 is ~26, for miR-34 is ~32 and for C2-miR is ~35 in 293FT cells measured by a real-time PCR approach. However, the miR-548 family members working on their targets are efficient as shown in this study, ~20 folds of relative level of exogenous upregulated C2-miR in HeLa cells (Fig. 1E) efficiently inhibited the tumor cell growth (Fig. 4C, E) . In fact, close to 8,000 Made1 are derived sequences in the human genome, and there are >1000 sequences with >50% sequence identities over the full-length of the canonical miR-548 sequence. Thus, it is reasonable that the aggregate expression of multiple family members may exert substantial regulatory effects on host gene targets. The results in Fig.   6A , B indicate that similar to C2-miR, the known miR-548 family members in lung tumors also expressed lower than in their adjacent non-tumor tissues. The reason why the sum of other known members of the miR-548 family was lower in lung tumors than in their adjacent nontumor tissues remains unclear; however, the fact that many miR-548 family members locate in fragile sites might partially explain the low expression of the miR-548 family. It is worthy in the future to explore the nature of lower expression of the miR-548 family in tumor than in normal (Table S4 ). The data represents the mean + standard deviation (SD) of 6 measurements (2 triple-sets) from 2 independent experiments. F, The pri-C2-miR was measured from 293FT and HeLa cells using the Northern blot. The left blot used the probe for detecting pri-miR-C2 at chromosome 1 (Chr1) and the right blot used the probe for detecting primiR-C2 at chromosome 3 (Chr3). Lane 1 and lane 4 indicated the RNA marker. adjacent non-tumor tissue were measured by using NanoString technology (Fig. S6A) . B, The relative levels of the sum of the miR-548 family members in 24 human cell lines (5 normal and 19 tumor cell lines) were measured using NanoString technology (Fig. S6A) 
